CoChat

Genotype-Selective Combination Therapies for Melanoma Identified by High-Throughput Drug Screening

Open access
Held, Matthew A., Langdon, Casey G., Platt, James T., Graham-Steed, Tisheeka, Liu, Zongzhi, Chakraborty, Ashok, Bacchiocchi, Antonella, Koo, Andrew, Haskins, Jonathan W., Bosenberg, Marcus W., Stern, David F. · 2013 · Cancer Discovery
Cited by 112

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

Resistance and partial responses to targeted monotherapy are major obstacles in cancer treatment. Systematic approaches to identify efficacious drug combinations for cancer are not well established, especially in the context of genotype. To address this, we have tested pairwise combinations of an array of small-molecule inhibitors on early-passage melanoma cultures using combinatorial drug screening. Results reveal several inhibitor combinations effective for melanomas with activating RAS or BRAF mutations, including mutant BRAF melanomas with intrinsic or acquired resistance to vemurafenib. Inhibition of both EGF receptor and AKT sensitized treatment-resistant BRAF mutant melanoma cultures to vemurafenib. Melanomas with RAS mutations were more resistant to combination therapies relative to BRAF mutants, but were sensitive to combinations of statins and cyclin-dependent kinase inhibitors in vitro and in vivo. These results show the use of combinatorial drug screening for discovering unique treatment regimens that overcome resistance phenotypes of mutant BRAF- and RAS-driven melanomas. Significance: We have used drug combinatorial screening to identify effective combinations for mutant BRAF melanomas, including those resistant to vemurafenib, and mutant RAS melanomas that are resistant to many therapies. Mechanisms governing the interactions of the drug combinations are proposed, and in vivo xenografts show the enhanced benefit and tolerability of a mutant RAS-selective combination, which is currently lacking in the clinic. Cancer Discov; 3(1); 52–67. ©2012 AACR. See related commentary by Al-Lazikani and Workman, p. 14 This article is highlighted in the In This Issue feature, p. 1

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-12-0408

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 112

Metadata

Authors
Held, M. A., Langdon, C. G., Platt, J. T., Graham-Steed, T., Liu, Z., Chakraborty, A., Bacchiocchi, A., Koo, A., Haskins, J. W., Bosenberg, M. W., & Stern, D. F.
Venue
Cancer Discovery
Published
2013-01-01
Volume
3
Issue
1
Pages
52-67
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2143152083
Cited by
112
References
17
FWCI
4.65
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Genotype-Selective Combination Therapies for Melanoma Identified by High-Throughput Drug Screening. https://app.cochat.ai/papers/10.1158/2159-8290.cd-12-0408
The paper
Held, M. A., Langdon, C. G., Platt, J. T., Graham-Steed, T., Liu, Z., Chakraborty, A., Bacchiocchi, A., Koo, A., Haskins, J. W., Bosenberg, M. W., & Stern, D. F. (2013). Genotype-Selective Combination Therapies for Melanoma Identified by High-Throughput Drug Screening. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-12-0408

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.